FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2188-2190 May 18, 2006 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Chambers, C. D. PubMed Citation

To the Editor: Several publications have recently reported an association between maternal treatment with selective serotonin-reuptake inhibitors (SSRIs) late in pregnancy and adverse outcomes in infants. These outcomes have included persistent pulmonary hypertension of the newborn (PPHN), as reported by Chambers et al. (Feb. 9 issue),¹ and the neonatal abstinence syndrome, a condition found in infants born with drug dependency.² Also, the Food and Drug Administration recently published a public health advisory concerning increased rates of congenital defects (and, specifically, heart defects) after the use of the SSRI paroxetine early in pregnancy.³ However, little information is available on the frequency . . . [Full Text of this Article]

This article has been cited by other articles:

• Moret, C., Isaac, M., Briley, M. (2009). Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharmacol 23: 967-974 [Abstract]  
• Cogswell, M. E., Bitsko, R. H., Anderka, M., Caton, A. R., Feldkamp, M. L., Sherlock, S. M. H., Meyer, R. E., Ramadhani, T., Robbins, J. M., Shaw, G. M., Mathews, T. J., Royle, M., Reefhuis, J., the National Birth Defects Prevention Study, (2009). Control Selection and Participation in an Ongoing, Population-based, Case-Control Study of Birth Defects: The National Birth Defects Prevention Study. Am J Epidemiol 170: 975-985 [Abstract] [Full Text]  
• Wisner, K. L., Sit, D. K.Y., Hanusa, B. H., Moses-Kolko, E. L., Bogen, D. L., Hunker, D. F., Perel, J. M., Jones-Ivy, S., Bodnar, L. M., Singer, L. T. (2009). Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes. Focus 7: 374-384 [Abstract] [Full Text]  
• Wisner, K. L., Sit, D. K.Y., Hanusa, B. H., Moses-Kolko, E. L., Bogen, D. L., Hunker, D. F., Perel, J. M., Jones-Ivy, S., Bodnar, L. M., Singer, L. T. (2009). Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes. Am. J. Psychiatry 166: 557-566 [Abstract] [Full Text]  
• Dubnov-Raz, G., Juurlink, D. N., Fogelman, R., Merlob, P., Ito, S., Koren, G., Finkelstein, Y. (2008). Antenatal Use of Selective Serotonin-Reuptake Inhibitors and QT Interval Prolongation in Newborns. Pediatrics 122: e710-e715 [Abstract] [Full Text]  
• Baldwin, D. S, Reines, E. H., Guiton, C., Weiller, E. (2007). Escitalopram Therapy for Major Depression and Anxiety Disorders. The Annals of Pharmacotherapy 41: 1583-1592 [Abstract] [Full Text]  
• Alwan, S., Reefhuis, J., Rasmussen, S. A., Olney, R. S., Friedman, J. M., the National Birth Defects Prevention Study, (2007). Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects. NEJM 356: 2684-2692 [Abstract] [Full Text]